DOCSLIB.ORG

Haematologica 1999;84:Supplement No. 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Haematologica 1999;84:Supplement No. 4 Educational Session 1 Chairman: W.E. Fibbe Haematologica 1999; 84:(EHA-4 educational book):1-3 Biology of normal and neoplastic progenitor cells Emergence of the haematopoietic system in the human embryo and foetus MANUELA TAVIAN,* FERNANDO CORTÉS,* PIERRE CHARBORD,° MARIE-CLAUDE LABASTIE,* BRUNO PÉAULT* *Institut d’Embryologie Cellulaire et Moléculaire, CNRS UPR 9064, Nogent-sur-Marne; °Laboratoire d’Étude de l’Hé- matopoïèse, Etablissement de Transfusion Sanguine de Franche-Comté, Besançon, France he first haematopoietic cells are observed in es. In this setting, the recent identification in animal the third week of human development in the but also in human embryos of unique intraembryonic Textraembryonic yolk sac. Recent observations sites of haematopoietic stem cell emergence and pro- have indicated that intraembryonic haematopoiesis liferation could be of particular interest. occurs first at one month when numerous clustered We shall briefly review here the successive steps of CD34+ Lin– haematopoietic cells have been identi- human haematopoietic development, emphasising fied in the ventral aspect of the aorta and vitelline the recent progresses made in our understanding of artery. These emerging progenitors express tran- the origin and identity of human embryonic and fetal scription factors and growth factor receptors known stem cells. to be acting at the earliest stages of haematopoiesis, and display high proliferative potential in culture. Primary haematopoiesis in the human Converging results obtained in animal embryos sug- embryo and foetus gest that haematopoietic stem cells derived from the As is the case in other mammals, human haema- para-aortic mesoderm – in which presumptive endo- topoiesis starts outside the embryo, in the yolk sac, thelium and blood-forming activity could be detect- then proceeds transiently in the liver before getting ed as early as 3 weeks in the human embryo by dif- stabilised until adult life in the bone marrow. Only T ferential expression of the CD34 and Flk-1/KDR genes lymphocytes are produced in the same tissue at – play an essential role in the foundation of definitive embryonic, foetal and postnatal stages. haematopoiesis. Aorta-associated CD34+ cells also The yolk sac represent a unique localised accumulation of primi- tive haematopoietic stem cells worthy of in-depth It is at about 18.5 days of development (early head molecular characterisation. Differential screening of process) that primitive haematopoietic cells appear a cDNA library has already revealed the expression of inside forming blood vessels in the intermediate novel genes in this population, one of which appears mesodermal cell layer of the human yolk sac wall. to be involved in the development of both haema- Studies on human haematopoietic cell emergence at these early stages are scarce, but our own observa- topoietic and endothelial cells. Active blood forma- 1,2 tion is observed in the liver and bone marrow by the tions suggest that the sequence described in animal end of the first trimester. Inception of haemato- models also applies to the human yolk sac: meso- poiesis occurs earlier in the liver, where CD34+ cells derm-derived clusters of primitive haematopoietic are detected as early as 30 days, than in the marrow, stem cells – the blood islands – develop in close asso- where haematopoietic cells are not observed before ciation with the endothelium of emerging blood ves- week 11. sels, possibly from a common ancestor cell or hae- Current interest in early human blood cell ontoge- mangioblast. The coexpression of the CD34 surface ny may be partly related to the growing use of foetal molecule by haematopoietic precursor cells and stem cells for transplantation at postnatal stages, endothelial cells can be traced back to these initial stages, which may support the hypothesis of their and to emerging cell and/or gene therapies of the 1,2 3 blood system in utero, which justify a thorough char- common origin. Migliaccio et al. described several acterisation of embryonic and foetal human haema- generations of clonogenic progenitors in the human topoiesis. In addition, the prenatal haematopoietic yolk sac from 4.5 weeks of development, including system is characterised by an outstandingly high rate pluripotential (CFU-GEMM), granulomonocytic of progenitor cell expansion, migration and differ- (CFU-GM) and erythroblastic progenitors (BFU-E entiation and hence can be seen as a privileged mod- and CFU-E). The human yolk sac starts regressing at el to identify novel factors involved in these process- about 45-50 days post-ovulation and virtually all clonogenic progenitors have disappeared from that tissue by week six. Correspondence: Bruno Péault, Unité 506 INSERM, Bâtiment Lavoisier; The liver Groupe Hospitalier Paul Brousse, 12, avenue Paul Vaillant-Couturier, th 94807 Villejiuf Cedex, France. Tel. international +33-1-45595263 – The liver emerges during the 4 week of develop- Fax: international +33.1.45595268 – E-mail: [email protected] ment when the hepatic bud, an endodermal out- 2 M. Tavian et al. growth of the foregut, invades the adjacent mesoder- Concepts on the filiation of the stem cells that mal septum transversum. These two tissues con- found definitive haematopoiesis have changed in the tribute hepatocyte cords and vascular sinuses, respec- past few years with the demonstration that, in ani- tively. We have detected CD45+CD34– haematopoi- mals, these emerge inside the embryo, and not in the etic cells from day 23 of development in the liver yolk sac as previously believed. In mice and birds the anlage while the first CD34+ haematopoietic progen- original blood-forming territory develops intrinsically itors could be recognised on day 30.1 In vitro colony- in the para-aortic splanchnopleural mesoderm con- forming cells, i.e. BFU-E, CFU-GM and, slightly later, stituting the presumptive aorta-gonad-mesonephros CFU-E have been indeed detected at 4.5-5 weeks in (AGM) region of the embryo and contributes, at pre- the liver rudiment, where their frequency then increas- liver stages, multilineage haematopoietic progenitors es dramatically, paralleling their sharp decline in the and eventually long-term reconstituting true haema- yolk sac.3 At the end of the first trimester, and topoietic stem cells. The existence in the human onwards, more primitive progenitors – CFU-GEMM embryo of an equivalent site of haematopoietic stem and HPP-CFC – have also been detected in the liver. cell generation has been suggested by the identifica- Earlier studies, confirmed by more recent immuno- tion, at 4-6 weeks of development, of numerous clus- histochemical approaches, have documented the tered CD34+ haematopoietic cells on the ventral extensive erythro-myeloid haematopoiesis that takes endothelium of the aorta and vitelline artery.1,6 These place extravascularly in the human embryonic and cells express surface antigens that typify early blood foetal liver, and have stressed the prominence of ery- cell progenitors, being CD45+, CD34++, CD31+, thropoiesis therein (reviewed in ref. #4). Other CD43+, CD44+, CD164+, but display no CD38 or lin- myeloid cells present in the haematopoietic liver are eage-specific markers. In situ hybridisation on embryo granulocytes, macrophages and rare megakaryocytes. sections and screening of cDNA libraries prepared B-lymphopoiesis has been traced in the liver from from these sorted aorta-adherent progenitors have about 9 weeks of gestation by detection of surface also revealed that they express genes known to be IgM+ cells. associated with the early steps of haematopoietic development, such as Tal1/SCL, c-myb, GATA-2, The bone marrow GATA-3, flk-1/VGEFR2 and c-kit.7 When directly A cartilaginous presumptive skeleton is present in assayed in methylcellulose, human intraembryonic the 6-8-week human embryo. Bone rudiments are aorta-associated CD34+ cells exhibited negligible + then surrounded by a dense network of CD34 capil- clonogenic potential. In contrast, following a 4-10- + laries, by CD68 monocytes and by osteoblast pre- day co-culture on murine bone marrow stromal cells cursors which all invade the diaphyseal cartilage at (MS-5 cell line), they generated about six times more 8.5-9 weeks. Incoming macrophages rapidly digest progenitors, which yielded large multilineage colonies the cartilage, leaving only intact small islets of chon- in methylcellulose, than the liver rudiment.6 Of note, drocytes that soon become surrounded by osteo- the para-aortic splanchnopleura – but no other intra- blasts, from which ossification proceeds in a typical- embryonic tissue – exhibited dramatic haematopoietic ly endochondral manner. In-between ossifying tra- potential in culture as early as day 23 of development, beculae, large vascular sinuses develop leading to the i.e. several days before CD34+ stem cells can actually completion, at about 10 weeks, of bone marrow cav- be identified on the aortic wall. This result, as well as ities.5 Marrow haematopoiesis starts during the 11th provocative semi-thin section histology pictures, sug- week of development in specialised mesodermal gest that haematopoietic stem cells emerge from structures or primary logettes, constituted by a loose mesoderm in that territory, and not merely migrate network of mesenchymal cells supported by dense fib- there from another location.6 rillar material and surrounding a central artery, inside Differential screening of a cDNA library built from which CD15+ granulocytes appear first, closely fol- sorted embryonic aorta-associated CD34+ cells with lowed by erythroid cells. Haematopoiesis then devel- probes prepared from embryonic liver and foetal bone ops dramatically in rapidly enlarging logettes which by marrow CD34+ stem cells is in progress. Several dif- week 15 are densely packed with cells of the erythroid ferentially expressed genes have already been found, and granulocytic series.5 one of which encodes a serine-threonine kinase which, interestingly, is co-expressed in all developing endo- Haematopoietic stem cell emergence in thelial and haematopoietic stem cells.7 This argues early human development for the existence of haemangioblasts, i.e. common prog- As mentioned above, the emergence of the CD34 enitors for vascular and blood cells.
Load more

Recommended publications
  • The Ageing Haematopoietic Stem Cell Compartment
    REVIEWS The ageing haematopoietic stem cell compartment Hartmut Geiger1,2, Gerald de Haan3 and M. Carolina Florian1 Abstract | Stem cell ageing underlies the ageing of tissues, especially those with a high cellular turnover. There is growing evidence that the ageing of the immune system is initiated at the very top of the haematopoietic hierarchy and that the ageing of haematopoietic stem cells (HSCs) directly contributes to changes in the immune system, referred to as immunosenescence. In this Review, we summarize the phenotypes of ageing HSCs and discuss how the cell-intrinsic and cell-extrinsic mechanisms of HSC ageing might promote immunosenescence. Stem cell ageing has long been considered to be irreversible. However, recent findings indicate that several molecular pathways could be targeted to rejuvenate HSCs and thus to reverse some aspects of immunosenescence. HSC niche The current demographic shift towards an ageing popu- The innate immune system is also affected by ageing. A specialized lation is an unprecedented global phenomenon that has Although an increase in the number of myeloid precur- microenvironment that profound implications. Ageing is associated with tissue sors has been described in the bone marrow of elderly interacts with haematopoietic attrition and an increased incidence of many types of can- people, the oxidative burst and the phagocytic capacity of stem cells (HSCs) to regulate cers, including both myeloid and lymphoid leukaemias, and both macrophages and neutrophils are decreased in these their fate. other haematopoietic cell malignancies1,2. Thus, we need individuals12,13. Moreover, the levels of soluble immune to understand the molecular and cellular mechanisms of mediators are altered with ageing.
    [Show full text]
  • Diverse T-Cell Differentiation Potentials of Human Fetal Thymus, Fetal Liver, Cord Blood and Adult Bone Marrow CD34 Cells On
    IMMUNOLOGY ORIGINAL ARTICLE Diverse T-cell differentiation potentials of human fetal thymus, fetal liver, cord blood and adult bone marrow CD34 cells on lentiviral Delta-like-1-modified mouse stromal cells Ekta Patel,1 Bei Wang,1 Lily Lien,2 Summary Yichen Wang,2 Li-Jun Yang,3 Jan Human haematopoietic progenitor/stem cells (HPCs) differentiate into S. Moreb4 and Lung-Ji Chang1 functional T cells in the thymus through a series of checkpoints. A conve- 1Department of Molecular Genetics and nient in vitro system will greatly facilitate the understanding of T-cell Microbiology, College of Medicine, University of Florida, Gainesville, FL, USA, 2Vectorite development and future engineering of therapeutic T cells. In this report, Biomedica Inc., Taipei, Taiwan, 3Department we established a lentiviral vector-engineered stromal cell line (LSC) of Pathology, Immunology and Laboratory expressing the key lymphopoiesis regulator Notch ligand, Delta-like 1 Medicine, University of Florida, Gainesville, (DL1), as feeder cells (LSC-mDL1) supplemented with Flt3 ligand (fms- 4 FL, USA, and Department of Medicine, like tyrosine kinase 3, Flt3L or FL) and interleukin-7 for the development University of Florida, Gainesville, FL, USA of T cells from CD34+ HPCs. We demonstrated T-cell development from human HPCs with various origins including fetal thymus (FT), fetal liver (FL), cord blood (CB) and adult bone marrow (BM). The CD34+ HPCs from FT, FL and adult BM expanded more than 100-fold before reaching the b-selection and CD4/CD8 double-positive T-cell stage. The CB HPCs, on the other hand, expanded more than 1000-fold before b-selection.
    [Show full text]
  • The Potential Role of Recombinant Activated FVII in the Management of Critical Hemato-Oncological Bleeding: a Systematic Review
    Bone Marrow Transplantation (2007) 39, 729–735 & 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00 www.nature.com/bmt REVIEW The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review M Franchini1, D Veneri2 and G Lippi3 1Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy; 2Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Universita` di Verona, Verona, Italy and 3Dipartimento di Scienze Biomediche e Morfologiche, Istituto di Chimica e Microscopia Clinica, Universita` di Verona, Verona, Italy Recombinant activated factor VII (rFVIIa) is an hemo- situations unresponsive to conventional therapy to control static agent that was originally developed for the excessive bleeding and reduce exposure to allogeneic blood. treatment of hemorrhage in patients with hemophilia and These include intracerebral hemorrhage, oral anticoagu- inhibitors.However, in the last few years rFVIIa has been lant-induced hemorrhage, thrombocytopenia, bleeding employed with success in a broad spectrum of congenital associated with hepatic failure, major surgery, trauma and acquired bleeding conditions.In this systematic review and life-threatening obstetrical, and gynecologic hemor- we present the current knowledge on the use of this drug in rhagic complications.5–9 patients suffering from hemato-oncological disorders, In this systematic review we have collected the available which are quite commonly complicated by severe hemor- data from the literature on the use of rFVIIa in hemato- rhage.On the whole, data in the literature suggest a oncological patients with severe bleeding, unresponsive to potential role for rFVIIa in the management of bleeding standard therapy.
    [Show full text]
  • Recent Developments in the Understanding and Management of Paroxysmal Nocturnal Haemoglobinuria
    review Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria Anita Hill, Stephen J. Richards and Peter Hillmen Department of Haematology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, UK Summary only one G6PD variant enzyme was present in the PNH red cells whereas both variants were present in the residual normal red Paroxysmal nocturnal haemoglobinuria (PNH) has been rec- cells, provided conclusive evidence of the clonal nature of PNH ognised as a discrete disease entity since 1882. Approximately a (Oni et al, 1970). It was clear by the 1980s that PNH cells were half of patients will eventually die as a result of having PNH. deficient in a large number of cell surface proteins, but it was Many of the symptoms of PNH, including recurrent abdominal unclear how this related to either the monoclonal nature of PNH pain, dysphagia, severe lethargy and erectile dysfunction, result or the haemolysis. The development of immortalised cell lines from intravascular haemolysis with absorption of nitric oxide with the PNH abnormality (both B- and T-cells lines) facilitated by free haemoglobin from the plasma. These symptoms, as well the rapid elucidation of the defect (Schubert et al, 1990; Hillmen as the occurrence of thrombosis and aplasia, significantly affect et al,1992;Nakakumaet al,1994).Itbecameclearthatavarietyof patients’ quality of life; thrombosis is the leading cause of proteins normally attached to the cell membrane by a glycolipid premature mortality. The syndrome of haemolytic-anaemia- structure, were found to be abnormal, and that this was due to a associated pulmonary hypertension has been further identified disruption in the glycosylphosphatidylinositol (GPI) biosyn- in PNH patients.
    [Show full text]
  • Autologous Haematopoietic Stem Cell Transplantation (Ahsct) for Severe Resistant Autoimmune and Inflammatory Diseases - a Guide for the Generalist
    This is a repository copy of Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/144052/ Version: Published Version Article: Snowden, J.A. orcid.org/0000-0001-6819-3476, Sharrack, B., Akil, M. et al. (5 more authors) (2018) Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist. Clinical Medicine, 18 (4). pp. 329-334. ISSN 1470-2118 https://doi.org/10.7861/clinmedicine.18-4-329 © Royal College of Physicians 2018. This is an author produced version of a paper subsequently published in Clinical Medicine. Uploaded in accordance with the publisher's self-archiving policy. Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/
    [Show full text]
  • Assessment of the Degree of Permanent Impairment Guide
    SAFETY, REHABILITATION AND COMPENSATION ACT 1988 – GUIDE TO THE ASSESSMENT OF THE DEGREE OF PERMANENT IMPAIRMENT EDITION 2.1 (CONSOLIDATION 1) This consolidation incorporates the Safety, Rehabilitation and Compensation Act 1988 – Guide to the Assessment of the Degree of Permanent Impairment Edition 2.1 (‘Edition 2.1’) as prepared by Comcare and approved by the Minister for Tertiary Education, Skills, Jobs and Workplace Relations on 2 November 2011 with effect from 1 December 2011 and as varied by the Safety, Rehabilitation and Compensation Act 1988 – Guide to the Assessment of the Degree of Permanent Impairment Edition 2.1 – Variation No.1 of 2011 (‘Variation 1 of 2011’) as approved by Comcare and approved by the Minister for Tertiary Education, Skills, Jobs and Workplace Relations on 29 November 2011 with effect from 1 December 2011. NOTES: 1. Edition 2.1 and Variation 1 of 2011 were each prepared by Comcare under subsection 28(1) of the Safety, Rehabilitation and Compensation Act 1988 and approved by the Minister under subsection 28(3) of that Act. 2. Edition 2.1 was registered on the Federal Register of Legislative Instruments as F2011L02375 and Variation 1 of 2011 was registered as F2011L02519. 3. This compilation was prepared on 30 November 2011 in accordance with section 34 of the Legislative Instruments Act 2003 substituting paragraph 3 (Application of this Guide) to Edition 2.1 as in force on 1 December 2011. 1 Federal Register of Legislative Instruments F2012C00537 GUIDE TO THE ASSESSMENT OF THE DEGREE OF PERMANENT IMPAIRMENT Edition 2.1 2 Federal Register of Legislative Instruments F2012C00537 INTRODUCTION TO EDITION 2.1 OF THE GUIDE 1.
    [Show full text]
  • Understanding Megakaryopoiesis and Thrombopoiesis Using Human Stem Cells Models
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Understanding Megakaryopoiesis And Thrombopoiesis Using Human Stem Cells Models Xiu Li Sim University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Developmental Biology Commons Recommended Citation Sim, Xiu Li, "Understanding Megakaryopoiesis And Thrombopoiesis Using Human Stem Cells Models" (2017). Publicly Accessible Penn Dissertations. 2586. https://repository.upenn.edu/edissertations/2586 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2586 For more information, please contact [email protected]. Understanding Megakaryopoiesis And Thrombopoiesis Using Human Stem Cells Models Abstract Human stem cell models (CD34+ hematopoietic progenitors, embryonic stem cells and induced pluripotent stem cells (iPSCs)) are powerful tools for the study of megakaryopoiesis and thrombopoiesis, particularly in situations where mouse models are unavailable or do not accurately recapitulate human physiology or development. In the first part of this thesis, we identified and characterized novel megakaryocyte (MK) maturation stages in MK cultures derived from human stem cells. An immature, low granular (LG) MK pool (defined yb side scatter on flow cytometry) gives rise to a mature high granular (HG) pool, which then becomes damaged by apoptosis and GPIbα (CD42b) shedding. We define an undamaged HG/CD42b+ MK subpopulation, which endocytoses fluorescently-labeled coagulation factor V (FV) from the medium into alpha-granules and releases functional FV+CD42b+ platelet-like particles in vitro and when infused into immunodeficient mice. Importantly, these FV+ platelets have the same size distribution as infused human donor platelets and are preferentially incorporated into clots after laser injury.
    [Show full text]
  • Probing Prothrombin Structure by Limited Proteolysis Laura Acquasaliente, Leslie A
    www.nature.com/scientificreports OPEN Probing prothrombin structure by limited proteolysis Laura Acquasaliente, Leslie A. Pelc & Enrico Di Cera Prothrombin, or coagulation factor II, is a multidomain zymogen precursor of thrombin that undergoes Received: 29 November 2018 an allosteric equilibrium between two alternative conformations, open and closed, that react diferently Accepted: 2 April 2019 with the physiological activator prothrombinase. Specifcally, the dominant closed form promotes Published: xx xx xxxx cleavage at R320 and initiates activation along the meizothrombin pathway, whilst the open form promotes cleavage at R271 and initiates activation along the alternative prethrombin-2 pathway. Here we report how key structural features of prothrombin can be monitored by limited proteolysis with chymotrypsin that attacks W468 in the fexible autolysis loop of the protease domain in the open but not the closed form. Perturbation of prothrombin by selective removal of its constituent Gla domain, kringles and linkers reveals their long-range communication and supports a scenario where stabilization of the open form switches the pathway of activation from meizothrombin to prethrombin-2. We also identify R296 in the A chain of the protease domain as a critical link between the allosteric open-closed equilibrium and exposure of the sites of cleavage at R271 and R320. These fndings reveal important new details on the molecular basis of prothrombin function. Te response of the body to vascular injury entails activation of a cascade of proteolytic events where zymo- gens are converted into active proteases1. In the penultimate step of this cascade, the zymogen prothrombin is converted to the active protease thrombin in a reaction catalyzed by the prothrombinase complex composed of the enzyme factor Xa, cofactor Va, Ca2+ and phospholipids.
    [Show full text]
  • Adhesive Receptor Mac-1 Coordinates the Activation of Factor X On
    Proc. Nati. Acad. Sci. USA Vol. 85, pp. 7462-7466, October 1988 Biochemistry Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade (leukocyte integrins/ADP/tissue factor/procoagulant response) DARIO C. ALTIERI, JAMES H. MORRISSEY, AND THOMAS S. EDGINGTON Vascular Biology Group, Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92037 Communicated by Seymour Klebanoff, June 21, 1988 ABSTRACT Monocytes initiate coagulation through reg- ligand specificity for factor X (20) suggests that Mac-1 ulated surface expression of tissue factor and local assembly of exhibits the multifunctional receptor versatility typical of a proteolytic enzymatic complex formed by tissue factor and other, partially related, integrin receptors (21, 22). factor VIl/activated factor VII. We now show that, in the These observations have now been extended to demon- absence of these initiating molecules, monocytes and cell lines strate that, in the absence of demonstrable TF or TF: of monocytic/myeloid differentiation can alternatively initiate VII/VIa complex, ADP-stimulated monocytes and myeloid coagulation after exposure to ADP. The molecular basis for this cells bearing Mac-1 directly convert surface-bound factor X procoagulant response consists oftwo distinct events. First, cell to a proteolytically active derivative characteristic of factor stimulation with ADP induces high-affinity binding of coagu- Xa. This appears to represent an additional mechanism of lation factor X to the surface-adhesive receptor Mac-1. Locally, initiating the coagulation protease cascade on the surface of Mac-i-concentrated factor X is then rapidly proteolytically cells.
    [Show full text]
  • Review Article Making Blood: the Haematopoietic Niche Throughout Ontogeny
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Stem Cells International Volume 2015, Article ID 571893, 14 pages http://dx.doi.org/10.1155/2015/571893 Review Article Making Blood: The Haematopoietic Niche throughout Ontogeny Mohammad A. Al-Drees,1,2 Jia Hao Yeo,3 Badwi B. Boumelhem,1 Veronica I. Antas,1 Kurt W. L. Brigden,1 Chanukya K. Colonne,1 and Stuart T. Fraser1,3 1 Discipline of Physiology, School of Medical Sciences, Bosch Institute, University of Sydney, Camperdown, NSW 2050, Australia 2LaboratoryofBoneMarrowandStemCellProcessing,DepartmentofMedicalOncology,MedicalOncologyandStemCellTransplant Center, Al-Sabah Medical Area, Kuwait 3Discipline of Anatomy & Histology, School of Medical Sciences, Bosch Institute, University of Sydney, Camperdown, NSW 2050, Australia Correspondence should be addressed to Stuart T. Fraser; [email protected] Received 24 March 2015; Accepted 10 May 2015 Academic Editor: Valerie Kouskoff Copyright © 2015 Mohammad A. Al-Drees et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Approximately one-quarter of all cells in the adult human body are blood cells. The haematopoietic system is therefore massive in scale and requires exquisite regulation to be maintained under homeostatic conditions. It must also be able to respond when needed, such as during infection or following blood loss, to produce more blood cells. Supporting cells serve to maintain haematopoietic stem and progenitor cells during homeostatic and pathological conditions. This coalition of supportive cell types, organised in specific tissues, is termed the haematopoietic niche.
    [Show full text]
  • Differential Contributions of Haematopoietic Stem Cells to Foetal and Adult Haematopoiesis: Insights from Functional Analysis of Transcriptional Regulators
    Oncogene (2007) 26, 6750–6765 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators C Pina and T Enver MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK An increasing number of molecules have been identified ment and appropriate differentiation down the various as candidate regulators of stem cell fates through their lineages. involvement in leukaemia or via post-genomic gene dis- In the adult organism, HSC give rise to differentiated covery approaches.A full understanding of the function progeny following a series of relatively well-defined steps of these molecules requires (1) detailed knowledge of during the course of which cells lose proliferative the gene networks in which they participate and (2) an potential and multilineage differentiation capacity and appreciation of how these networks vary as cells progress progressively acquire characteristics of terminally differ- through the haematopoietic cell hierarchy.An additional entiated mature cells (reviewed in Kondo et al., 2003). layer of complexity is added by the occurrence of different As depicted in Figure 1, the more primitive cells in the haematopoietic cell hierarchies at different stages of haematopoietic differentiation hierarchy are long-term ontogeny.Beyond these issues of cell context dependence, repopulating HSC (LT-HSC),
    [Show full text]
  • Intersections of Lung Progenitor Cells, Lung Disease and Lung Cancer
    LUNG SCIENCE CONFERENCE LUNG PROGENITOR CELLS Intersections of lung progenitor cells, lung disease and lung cancer Carla F. Kim1,2,3 Affiliations: 1Stem Cell Program, Division of Hematology/Oncology and Division of Respiratory Disease, Boston Children’s Hospital, Boston, MA, USA. 2Dept of Genetics, Harvard Medical School, Boston, MA, USA. 3Harvard Stem Cell Institute, Cambridge, MA, USA. Correspondence: Carla F. Kim, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA. E-mail: [email protected] @ERSpublications Stem cell biology has brought new techniques to the lung field and has elucidated possible therapeutic pathways http://ow.ly/h74x30cA6Lo Cite this article as: Kim CF. Intersections of lung progenitor cells, lung disease and lung cancer. Eur Respir Rev 2017; 26: 170054 [https://doi.org/10.1183/16000617.0054-2017]. ABSTRACT The use of stem cell biology approaches to study adult lung progenitor cells and lung cancer has brought a variety of new techniques to the field of lung biology and has elucidated new pathways that may be therapeutic targets in lung cancer. Recent results have begun to identify the ways in which different cell populations interact to regulate progenitor activity, and this has implications for the interventions that are possible in cancer and in a variety of lung diseases. Today’s better understanding of the mechanisms that regulate lung progenitor cell self-renewal and differentiation, including understanding how multiple epigenetic factors affect lung injury repair, holds the promise for future better treatments for lung cancer and for optimising the response to therapy in lung cancer. Working between platforms in sophisticated organoid culture techniques, genetically engineered mouse models of injury and cancer, and human cell lines and specimens, lung progenitor cell studies can begin with basic biology, progress to translational research and finally lead to the beginnings of clinical trials.
    [Show full text]